Efficacy of a Foot Strengthening Protocol on Sport Performance Kinetics (PRP-Pied-PERF)

This randomized controlled trial aims to explore the effect of a foot strengthening protocol on toe flexion strength, foot deformation and morphology as well as kinetics during sprinting, cutting and jumping in healthy athletes (18-40 completed years). The study consists of a 4 weeks control period, followed by 8 weeks intervention period and 4 weeks follow up

Study Overview

Detailed Description

During the first period participants are unaware of their allocation, while in the intervention period they will be allocated to a train intervention or a control group (habits maintenance). The primary outcome is the toes maximal voluntary isometric plantarflexion. The treatment effectiveness estimand is the same as in a pretest-posttest case control study, considering the end of the control period as pre-point. An estimation of the individual variability in response to the treatment will be provided.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Saint-Étienne, France, 42055
        • CHU de Saint-Etienne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria :

  • To be affiliated in the federation of one of the following sports : soccer, handball, rugby, basketball or track and field;
  • To practice their respective sport more than two times per week;
  • Be affiliated or beneficiary of a social security insurance;
  • Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved.
  • Licensed in a tennis club (FFT) and in a volleyball club (FFVolley)

Exclusion criteria :

  • Use of pharmacological therapy to match gander identity;
  • Have an abnormal range of motion of the toes and/or ankle;
  • Have any kind of ankle or foot pain (self-defined and self-reported by the FAAM questionnaire) in the previous 6 months;
  • Have a previous injury or surgery of the lower limb in the previous 6 months;
  • Have a neurological or vestibular deficit that may affect walking or balance (lumbar-sacral radiculopathy, peripheral nerve pathology, Marfan or Eehlers-Danlos syndrome, etc.);
  • Have contraindication to neuromuscular electrical stimulation (pacemaker, seizure disorders, pregnancy);
  • Have a previous foot strengthening experience in the past 6 months for at least 2 weeks and more than one session per week;
  • Participate at the same time in another medical interventional experiment or have participated in such a study in the 30 days preceding this study;
  • Being unable to understand the purpose and conditions of the study, and to give consent;
  • Being deprived of liberty or under guardianship.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Training group (PRP)
Participants benefiting from an 8-week muscle strengthening program (PRP)

This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :

  • Maximum muscle strength of the foot
  • Foot muscle morphology
Sham Comparator: Control group
Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
maximal isometric joint flexion muscle strength MTP (in N)
Time Frame: Change from baseline to Week 18
It will be measured using an ergometer composed of a 3-dimensional force sensor (Nano 25, ATI Industrial Automation, Garner, NC) during the 3 periods of the randomized controlled trial (control, intervention and follow-up) and repeatedly each week during the intervention protocol.
Change from baseline to Week 18

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Foot deformity
Time Frame: Change from baseline to Week 18

It's a composite outcome :

Foot deformity will be assessed with the help of the system (Arch Height Index Measurement System, JAKTOOL Corporation, Cranberry, NJ) measuring the following variables (in cm): height of the navicular, total length of the foot, truncated length of the foot, width of the medial foot and height of the dorsal arch when the participant is sitting and then when standing on one foot.

Change from baseline to Week 18
Foot posture
Time Frame: Change from baseline to Week 18
Foot posture will be measured using the Foot Posture Index (FPI-6).
Change from baseline to Week 18
Morphology of the foot muscles
Time Frame: Change from baseline to Week 18
The morphology of the foot muscles will be evaluated by measuring with the AixPlorer Ultrasonic scanner, version 6.1.1; Supersonic Imagine, Aix-en-Provence, France.
Change from baseline to Week 18
general stiffness of the foot-ankle complex
Time Frame: Change from baseline to Week 18
The general stiffness of the foot-ankle complex will be evaluated using an optical measurement system (Optojump Next, Microgate, Bolzano, 113 Italy) during 6 maximal jumps with knees stretched.
Change from baseline to Week 18
propulsion impulse during jumps
Time Frame: Change from baseline to Week 18
The propulsion impulse during jumps will be evaluated using 2 force platforms embedded in the ground under each foot (Kistler, Winterhur, Switzerland) to collect kinetic force parameters in all 3 spatial dimensions during vertical and horizontal jumps at a sampling frequency of 2000 Hz.
Change from baseline to Week 18
propulsion impulse during direction changes
Time Frame: Change from baseline to Week 18
The propulsion impulse during direction changes will be evaluated using a ground embedded force platform (Kistler, Winterhur, Switzerland) to collect force kinetic parameters in all 3 spatial dimensions during 90° direction changes at a sampling rate of 2000 Hz.
Change from baseline to Week 18
propulsion impulse during sprinting
Time Frame: Change from baseline to Week 18
The propulsion impulse during sprinting will be evaluated using 6 force platforms embedded in the ground (Kistler, Winterhur, Switzerland) allowing to collect kinetic parameters of forces in the 3 dimensions of space at a sampling frequency of 2000 Hz.
Change from baseline to Week 18

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pascal EDOUARD, PhD, Centre Hospitalier Universitaire de Saint Etienne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 3, 2023

Primary Completion (Actual)

February 14, 2024

Study Completion (Actual)

June 13, 2024

Study Registration Dates

First Submitted

October 3, 2022

First Submitted That Met QC Criteria

October 6, 2022

First Posted (Actual)

October 10, 2022

Study Record Updates

Last Update Posted (Actual)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 13, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 21CH247
  • ANSM (Other Identifier: 2025-A01697-42)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Athletes

Clinical Trials on Progressive foot strengthening protocol

Subscribe